Increased plasma homocysteine and allantoin levels in coronary artery disease: Possible link between homocysteine and uric acid oxidation

Acta Cardiologica

Volumn 61, Issue 4, 2006, Pages 432-439

  Özkan, Yeşim ^a   Yardim Akaydin, Sevgi ^a   Imren, Ersin ^b   Torun, Meral ^a   Şimşek, Bolkan ^a  

^a GAZI UNIVERSITY   (Turkey)

^b 29 Mayis Hospital   (Turkey)

Author keywords

Allantoin; Coronary artery diseases; Free radicals; Homocysteine; Oxidative stress; Uric acid

Indexed keywords

ALLANTOIN; CREATININE; HOMOCYSTEINE; URIC ACID;

ARTICLE; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIAGNOSTIC KIT; GROUPS BY AGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERHOMOCYSTEINEMIA; OXIDATION; SEX DIFFERENCE;

ADULT; AGED; ALLANTOIN; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY DISEASE; FEMALE; HOMOCYSTEINE; HOMOCYSTINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES; URIC ACID;

EID: 33748416862     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.61.4.2017305     Document Type: Article

References (49)

1. Langman LJ, Cole DEC. Homocysteine: cholesterol of the 90's? Clin Chim Acta 1999; 286: 63-80.
2. Stamler JS, Slivka A. Biological chemistry of thiols in the vasculature and in vascular-related disease. Nutr Rev 1996; 54: 1-30.
3. Jakubowski H. Protein N-homocysteinylation: implications for atherosclerosis. Biomed Pharmacother 2001; 55: 443-7.
4. Eberhardt RT, Forgione MA, Cap A, Leopold JA, Rudd MA, Trolliet M, Heydrick S, Stark R, Klings ES, Moldovan NI, Yaghoubi M, Goldschmidt-Clermont PJ, Farber HW, Cohen R, Loscalzo J. Endothelial dysfunction in a murine model for hyperhomocyst(e)inemia. J Clin Invest 2000; 106: 483-91.
5. Lentz SR, Dayal S, Arning E, Bottiglieri T, Sigmund CD, Faraci FM. Role of superoxide in cerebral vascular dysfunction in hyperhomocysteinemic mice. Circulation 2002; 106: II-111.
6. Ungvari Z, Csiszar A, Bagi Z, Koller A. Impaired nitric oxide-mediated flow-induced coronary dilatation in hyperhomocysteinemia: morphological and functional evidence for increased peroxynitrite formation. Am J Pathology 2002; 161: 145-53.
7. Dalay S, Brown KL, Weydert CJ. Deficiency of glutathione peroxidase-1 sensitizes hyperhomocystinemic mice to endothelial dysfunction. Arterioscler Thromb Vasc Biol 2002; 22: 1996-2002.
8. Sood HS, Hunt MJ, Tyagi SC. Peroxisome proliferator ameliorates endothelial dysfunction in a murine model of hyperhomocysteinemia. Am J Physiol 2003; 284: L333-L341.
9. The Hypertension Detection and Follow-up Program Cooperative Research Group. Mortality findings for stepped-care and referred-care participants in the hypertension detection and follow-up program, stratified by other risk factors. Prev Med 1985; 14: 312-35.
10. Bengtsson S, Lapidus L, Stendahl C, Waldenstrom J. Hyperurisemia and risk of cardiovascular disease and over-all death: a 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Acta Med Scand 1988; 224: 549-55.
11. Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1995; 141: 637-44.
12. Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J 1985; 114: 413-9.
13. Iribarren C, Folsom AR, Eckfeldt JH, McGrovern PG, Nieto FJ. Correlates of uric acid and its association with asymptomatic carotid atherosclerosis: The ARIC study. Ann Epidemiol 1996; 6: 331-40.
14. Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis 2000; 148: 131-9.
15. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defence in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981; 78: 6858-62.
16. Yardim-Akaydin S, Sepici A, Özkan Y, Torun M, Şimşek B, Sepici V. Oxidation of uric acid in rheumatoid arthritis: is allantoin a marker of oxidative stress? Free Rad Res 2004; 38: 623-8.
17. Ogihara H, Ogihara T, Miki M, Yasuda H, Mino M. Plasma copper and antioxidant status in Wilson's disease. Pediatr Res 1995; 37: 219-26.
18. Moison RM, Beaufort AJ, Haasnoot AA, Dubbelman TMAR, van Zoeren-Grobben D, Berger HM. Uric acid and ascorbic acid redox ratios in plasma and tracheal aspirate of preterm babies with acute and chronic lung disease. Free Rad Biol Med 1997; 23: 226-34.
19. Kock R, Delvoux B, Sigmund M, Greiling H. A comparative study of the concentrations of hypoxanthine, xanthine, uric acid and allantoin in the blood of normals and patients with acute myocardial infarction and other ischemic diseases. Eur J Clin Chem Clin Biochem 1994; 32: 837-42.
20. Zitnanova I, Korytar P, Aruoma OI. Uric acid and allantoin levels in Down syndrome: antioxidant and oxidative stress mechanisms? Clin Chim Acta 2004; 341: 139-46.
21. Vester B, Rasmussen K. High performance liquid chromatography method for rapid and accurate determination of homocysteine in plasma and serum. Eur J Clin Chem Clin Biochem 1991; 29: 549-54.
22. Krijt J, Vacková M, Kožich V. Measurement of homocysteine and other aminothiols in plasma: advantages of using tris (2-carboxyethyl) phosphine as reductant compared with tri-n-buthylphosphine. Clin Chem 2001; 47: 1821-8.
23. Hatch LL, Sevanian A. Measurement of uric acid, ascorbic acid, and related metabolites in biological fluids. Anal Biochem 1984; 138: 324-8.
24. Arnesen E, Refsum H, Bønaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995; 24: 704-9.
25. Chasan-Taber L, Seihub J, Rosenberg IH. A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. J Am Coll Nutr 1996; 15: 136-43.
26. Stehouwer CD, Weijenberg MP, Van den Berg M, Jacobs C, Feskens EJ, Kromhout, D. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10-year follow-up. Arterioscler Thromb Vasc Biol 1998; 18: 1895-1901.
27. Bostom AG, Silbershayz H, Rosenberg IH. Nonfasting plasma total homocysteinemia levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 1999; 159: 1077-80.
28. Koning ABL, Werstuck GH, Zhou J, Austin RC. Hyperhomocysteinemia and its role in the development of atherosclerosis. Clin Biochem 2003; 36: 431-41.
29. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996; 98: 5-7
30. Tang L, Mamotte CD, Van Bockxmeer FM, Taylor RR. The effect of homocysteine in DNA synthesis in cultured human vascular smooth muscle. Atherosclerosis 1998; 136: 169-173.
31. Yamamato M, Hara H, Adachi T. Effect of homocysteine on the binding of extracellular-superoxide dismutase to the endothelial cell surface. FEBS Lett 2000; 486: 159-62.
32. Outinen PA, Sood SK, Pfeifer SI. Homocysteine-Induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells. Blood 1999; 94: 959-67.
33. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986; 77: 1370-6.
34. Cavalca V, Cighetti G, Bamonti F. Oxidative stress and homocysteine in coronary artery disease. Clin Chem 2001; 47: 887-92.
35. Blom HJ, Kleinveld HA, Boers GHJ. Lipid peroxidation and susceptibility of low density lipoprotein to in vitro oxidation by hyperhomocysteinemia. Eur J Clin Invest 1995; 25: 140-54.
36. Lang D, Kredan MB, Moat SJ. Homocysteine-induced inhibition of endothelium-dependent relaxation in rabbit aorta: role for superoxide anions. Arterioscler Thromb Vasc Biol 2000; 20: 422-7.
37. Yeum KJ, Russell RM, Krinsky NI, Aldini G. Biomarkers of antioxidant capacity in the hydrophilic and lipophilic compartments of human plasma. Arch Biochem Biophysc 2004; 430; 97-103.
38. Alderman MH. Uric acid and cardiovascular risk. Curr Opinion Pharm 2002; 2: 126-30.
39. Abuja PM. Ascorbate prevents prooxidant effects of urate in oxidation of human low density lipoprotein. FEBS Lett 1999; 446: 305-8.
40. Filipe P, Haigle J, Freitas J. Anti- and pro-oxidant effects of urate in copper-induced low-density lipoprotein oxidation. Eur J Biochem 2002; 269: 5474-83.
41. Teng RJ, Ye YZ, Parks DA, Beckman JS. Urate produced during hypoxia protects heart proteins from peroxynitrite-mediated protein nitration. Free Rad Biol Med 2002; 33: 1243-9.
42. Kanellis J, Kang DK. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol 2005; 25: 39-42.
43. Hak AE, Polderman KH, Westendorp IC, Jacobs C, Hofman A, Witteman JC, Stehouwer CD. Increased plasma homocysteine after menopause. Atherosclerosis 2000; 149: 163-8.
44. Morris MS, Jacques PF, Selhub J, Rosenberg IH. Total homocysteine and estrogen status indicators in the third national health and nutrition examination survey. Am J Epidemiol 2000; 152: 140-8.
45. Kang SS, Wong PWK, Cook HY, Norusis M, Messer JV. Protein-bound homocyst(e)ine: A possible risk factor for coronary artery disease. J Clin Invest 1986; 77: 1482-6.
46. Coull BM, Malinow R, Beamer N, Sexton G, Nordt F, Garmo P. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke 1990; 21: 572-6.
47. Malinow MnR, Levenson J, Giral P. Role of blood pressure, uric acid, and hemorheological parameters on plasma homocyst(e)ine concentration. Atherosclerosis 1995; 114: 175-83.
48. Lussier-Caca S, Xhignesse M, Piolot A, Selhub J, Davignon J, Genest J. Plasma total homocysteine in healthy subjects: sex-specific relation with biological traits. Am J Clin Nutr 1996; 64: 587-93.
49. Motti C, Gnasso A, Bernardini S. Common mutation in methylenetetrahydrofolatereductase. Correlation with homocysteine and other risk factors for vascular disease. Atherosclerosis 1998; 139: 377-83.